The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, X, n.sup.1, n.sup.2, and n.sup.3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

The present disclosure provides immunes cells comprising a radiolabeled tracer useful in imaging tests such as positron emission topography (PET)/computed tomography (CT) scans. The present disclosure further includes engineered cells comprising a chimeric antigen receptor (CAR) further comprising a nucleic acid molecule comprising a ligand binding domain capable of binding to radiolabeled tracer. This disclosure also includes methods for assessing the efficacy or toxicity of an adoptive cell therapy in a subject, methods for detecting the quantity of engineered T cells in a subject, methods for monitoring an immunotherapy treatment in a subject and methods of imaging engineered T cells in a subject. In some embodiments, the radiolabeled tracer is [.sup.18F]fluoropropyl-trimethoprim ([.sup.18F]FPTMP).

The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.

A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.

Fluoridated organofluoroborates comprising at least one .sup.18F atom and precursors thereto, for use in PET scanning.

A neutron capture therapy system capable of eliminating amyloid -protein includes a neutron capture therapy device and a compound capable of specifically binding to the amyloid -protein having a nuclide with a large thermal neutron capture cross section. The neutron capture therapy device includes a neutron source, a beam shaping assembly and a collimator, the neutrons released by the neutron source pass through the beam shaping assembly and are slowed into a neutron beam within a certain energy range. The neutron beam irradiates the compound, and the energy generated by the reaction thereof can destroy the structure of the amyloid -protein. The neutron capture therapy system can specifically eliminate the amyloid -protein, and reduce the damage to the tissues surrounding the amyloid -protein.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.